Lymphoma & Plasma Cell Disorders

News

Mogamulizumab prolongs PFS in CTCL

Mogamulizumab is an effective treatment option for relapsed/refractory cutaneous T-cell lymphoma (CTCL), according to researchers. In the phase 3...

News

Group releases new CLL guidelines

Fludarabine, cyclophosphamide, and rituximab are recommended as initial therapy for fit patients with chronic lymphocytic leukemia (CLL) who do...

Pages